Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of its Denosumab Injection to the overseas ...

Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Samsung Bioepis launches denosumab biosimilars, Obodence and Xbryk in Europe: Incheon, Korea Tuesday, December 2, 2025, 14:00 Hrs [IST] Samsung Bioepis Co., Ltd. announced the lau ...

For Immediate Release Chicago, IL – December 9, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition ...

Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...